Rani Therapeutics launches RT-111 development program

Robotic pill company Rani Therapeutics (Nasdaq:RANI) has begun developing RT-111, a RaniPill GO capsule containing a biosimilar of Johnson & Johnson’s (NYSE:JNJ) Stelara (ustekinumab).

The company anticipates that RT-111 could potentially treat psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis.

The FDA first approved Stelara in 2009 for psoriasis.

Stelara is available in intravenous and subcutaneous doses. It is most commonly administered subcutaneously.

“Ustekinumab has helped thousands of patients with inflammatory autoimmune diseases, but today the treatment requires regular long-term injections,” said Talat Imran, Rani CEO, in a news release.

The company hopes that RT-111 will reduce the treatment burden for ustekinumab candidates.

“We are increasingly excited about the potential of the RaniPill platform to provide patients with oral replacements to current injectable standards of care, and we expect that…

Read more
  • 0